Dr. Mino-Kenudson is Professor of Pathology at Harvard Medical School and the
director of Pulmonary Pathology service at Massachusetts General Hospital, Boston, USA. She has been conducting translational research on lung cancer in collaboration with molecular pathologists, thoracic oncologists, and basic scientists. She and her team have described the morphology of molecularly annotated and/or biologically aggressive lung adenocarcinomas. They were the first group to report the signet ring cell morphology associated with ALK rearranged lung adenocarcinomas, as well as tumor islands, which associate with KRAS mutations and unfavorable patient outcomes, and are now considered to represent airspace invasion. They also documented the utility of clinical testing to identify molecularly defined lung adenocarcinomas. The ALK and ROS1 FISH, as well as ALK immunohistochemistry (the clone D5F3) that they reported, have significantly facilitated the detection of patients with actionable gene arrangements (game-changing innovations). She and her collaborators have also been actively investigating resistant mechanisms for EGFR, ALK and ROS1 tyrosine kinase inhibitors that will aid in identifying appropriate treatment for those patients after development of resistance to the inhibitors. She has contributed to the 2015 WHO classification of lung tumours and is a member of the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC).
